Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]
Rhythmlink Names New CEO to Helm Next Growth Phase
Summary: Rhythmlink Global has appointed Paul Buckman as CEO, succeeding co-founder Shawn Regan, who gets chairman. Buckman’s history in health-related products will guide Rhythmlink in growing its neurodiagnostic enterprise. Regan will go on his involvement as a strategic … [Read more...]
Phase 3 Study of Pitolisant for Prader-Willi Syndrome Begins
Harmony Biosciences Holdings Inc initiated its world-wide section 3 registrational demo, the TEMPO research, to examine the basic safety and efficacy of pitolisant as a remedy for excessive daytime sleepiness (EDS) and behavioral indications in sufferers aged 6 yrs and more … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]
AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial
Summary: In the SYMPHONY stage 3 trial, Axsome Therapeutics’ AXS-12 considerably lowered weekly cataplexy assaults and improved indications of narcolepsy, which include extreme daytime sleepiness, cognitive operate, and over-all ailment severity, when compared to placebo. The … [Read more...]